Abdel-Rahman Omar, ElHalawani Hesham
Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Future Oncol. 2015;11(21):2949-61. doi: 10.2217/fon.15.178. Epub 2015 Sep 30.
We performed a meta-analysis of the risk of hematological adverse events associated with ramucirumab.
Eligible studies included randomized Phase II and III trials of patients with solid tumors on ramucirumab, describing events of anemia, leucopenia, neutropenia, febrile neutropenia and thrombocytopenia.
A total of 11 clinical trials were considered eligible for the meta-analysis. The relative risks of all-grade anemia, leucopenia, neutropenia, febrile neutropenia and thrombocytopenia were 0.88 (95% CI: 0.80-0.96; p = 0.007), 1.13 (95% CI: 0.85-1.49; p = 0.41), 1.25 (95% CI: 1.08-1.44; p = 0.002), 1.63 (95% CI: 1.30-2.06; p < 0.0001), 1.91 (95% CI: 1.52-2.42; p < 0.00001), respectively.
Our meta-analysis has demonstrated an increased risk of febrile neutropenia, all-grade and high-grade neutropenia and thrombocytopenia with ramucirumab-based treatment compared with control.
我们对与雷莫西尤单抗相关的血液学不良事件风险进行了一项荟萃分析。
符合条件的研究包括雷莫西尤单抗治疗实体瘤患者的随机II期和III期试验，描述了贫血、白细胞减少、中性粒细胞减少、发热性中性粒细胞减少和血小板减少事件。
共有11项临床试验被认为符合荟萃分析的条件。所有级别贫血、白细胞减少、中性粒细胞减少、发热性中性粒细胞减少和血小板减少的相对风险分别为0.88（95%CI：0.80 - 0.96；p = 0.007）、1.13（95%CI：0.85 - 1.49；p = 0.41）、1.25（95%CI：1.08 - 1.44；p = 0.002）、1.63（95%CI：1.30 - 2.06；p < 0.0001）、1.91（95%CI：1.52 - 2.42；p < 0.00001）。
我们的荟萃分析表明，与对照组相比，基于雷莫西尤单抗的治疗使发热性中性粒细胞减少、所有级别和高级别中性粒细胞减少以及血小板减少的风险增加。
